News regarding Lintec. I don’t know how credible the site is, but the article is certainly well-written.
https://www.ainvest.com/news/lintec-euv-pellicle-bet-real-customers-building-2605/
Once TSMC’s Fab 3 pellicle line ramps, and once Samsung’s Taylor fab deployment scales, Lintec’s pricing power in those accounts will erode. The question becomes whether it can pivot to serving second-tier customers - Intel, SMIC, Rapidus, and the foundry tier that doesn’t have in-house pellicle capability - fast enough to sustain the revenue multiple the stock now implies.
Competitors using In-house (Canatu) are slightly trailing behind
Mitsui Chemicals is also in the game - it announced mass production facilities for CNT pellicles at its Iwakuni-Ohtake Works in May 2024. But Lintec’s integrated approach, combining the CNT membrane with proprietary coating formulations and a dedicated Tsukuba production hub, gives it the architecture lead.
Lintec is supposedly ahead of Mitsui, thanks to better coating. Based on what I’ve researched about EUV, pellicle coating will be important in the future. This is how a longer lifespan for pellicles under hydrogen plasma is achieved.